TearScience develops devices that provide clinical identification and treatment of evaporative dry eye. TearScience's integrated, in-office system enables eye care professionals to effectively address a root cause of evaporative dry eye. The company's LipiView is a device used for observing the tear film. LipiView captures images of the tear film, processing 14 million pixels per second - more than a billion data points in total - for precise evaluation in less than 5 minutes.
TearScience has filed 80 patents.
Medical imaging, Image processing, Ophthalmology, Microscopy, Radiopharmaceuticals
Medical imaging, Image processing, Ophthalmology, Microscopy, Radiopharmaceuticals
Latest TearScience News
Jun 1, 2023
Published by: Disclosures: Kading reports financial relationships with Alcon, Allergan, Avellino, Bausch + Lomb, BioTissue, CooperVision, Dompe, Euclid, Eye Promise, Medmont, Novartis, Ocuphire, Oculus, Orasis, Santen, Sun Pharma, TearScience, Thea, Trukera Medical, Valley Contax, Visus Therapeutics, VSP and Zeiss. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact email@example.com . Back to Healio Even if your practice is pressed for time, you have time to diagnose dry eye disease, treat it and track your results. Diagnosis doesn’t take a lot of extra equipment — just simple steps you can fit into a basic exam. Dry eye disease (DED) is chronic, progressive and highly prevalent, which makes screening extremely important. Early detection and management of DED can prevent downstream effects, from chronic discomfort and contact lens dropout to meibomian gland atrophy and corneal scarring. You can follow up with periodic medical visits, just as you do with any other chronic condition you’re treating. And because DED causes fluctuating vision, patients both see and feel better when DED is well-managed. Start with a screening questionnaire In my practice, patients fill out a simple, effective symptom questionnaire with the rest of their paperwork. The Ocular Surface Disease Index (OSDI) or Standard Patient Evaluation of Eye Dryness questionnaires are both excellent. For efficiency and ease of use, I choose to use the Symptom Assessment In Dry Eye questionnaire, which is very quick (just two intuitive questions) and has accuracy equivalent to OSDI (Amparo F, et al). My patients’ questionnaire scores help inform my exam. Perform a basic dry eye evaluation Just as a screening questionnaire tells us whether the patient is experiencing symptoms of DED, our exam can reveal the signs. We always evaluate patients for redness or inflammation during a routine slit lamp examination, but paired with results from the questionnaire, these signs may support a diagnosis of DED. I also look for telangiectasia, which can accompany ocular rosacea, a common cause of DED. Next, I look for evidence of damage on the conjunctiva or cornea with fluorescein dye or lissamine green staining. With dye on the eye, I also measure the tear meniscus height (the lacrimal lake) to understand the patient’s tear volume (< 0.2 mm is below normal). As an alternative, you might choose to use a Schirmer’s test or technology to quantify the tear volume. Finally, I apply gentle pressure (about 1.25 g/mm2) to the meibomian glands in the lower eyelid and count how many meibomian glands are yielding liquid secretions (MGYLS). Six or fewer MGYLS indicate meibomian gland dysfunction (MGD). At this point, if the questionnaire shows that a patient has symptoms of DED and/or my slit lamp exam shows signs, such as corneal or conjunctival staining or low tear volume, we can confidently diagnose DED, initiate the first steps of management, and schedule a medical visit to dig in more and develop a treatment plan. Initial steps of DED management Although patients with DED need medical visits for in-depth management, we can get patients started with early care before they return for that visit. I have all patients start using a “dry eye bundle” that includes daily warm compresses, omega supplements and lid scrubs. I also want patients to proactively use preservative-free artificial tears in the morning and every few waking hours to help hydrate, nourish and calm the ocular surface without risk of ocular surface toxicity. With so many confusing artificial tear options available, I’m very clear about the tear I want patients to use. I’ve been starting patients on iVizia (Similasan Corp.), a drop with povidone — a lubricating, viscosity-enhancing ingredient — as well as hyaluronic acid and trehalose, which protect and rehydrate the eye (Liu Z, et al). The drops come in a safe, convenient multidose bottle that my patients find easy to use. Some patients’ conditions benefit from other early treatments. For example, if there is staining or a patient has red, inflamed eyes, I immediately order a short-term steroid such as Eysuvis (loteprednol etabonate ophthalmic suspension 0.25%, Kala Pharmaceuticals), rather than waiting for the medical visit. Recheck in 2 to 4 weeks When patients return for a medical visit, I track their progress using the same tests (questionnaire, slit lamp exam, staining and tear meniscus measurement). I compare the results against baseline while I talk to patients about their experience in the last few weeks. If there are positive results, then the dry eye bundle, including proactive artificial tears, may be enough. If there’s no improvement or too little, patients continue first-line therapy while adding second-line treatments. At this point, you can choose to perform second-line treatments yourself, such as prescribing immunomodulator drops like Restasis (cyclosporine ophthalmic emulsion 0.05%, AbbVie) or Xiidra (lifitegrast ophthalmic solution 5%, Novartis), or refer the patient to a specialist. In my DED specialty practice, I perform additional tests for inflammation, tear quality, tear meniscus height and tear breakup time, MGD and other factors as needed. I also perform thermal pulsation (iLux, Alcon; LipiFlow, Johnson & Johnson Vision) for inspissated meibum, light-based therapy (OptiLight, Lumenis) for both MGD and lacrimal functional unit dysfunction, and severe DED treatments such as amniotic membrane, amniotic or autologous serum, or platelet-rich plasma eye drops. Keep following up To manage DED effectively, we need to see patients regularly and track their results. A good rule of thumb is to see patients once a month to track their progress with at-home care and prescriptions, and then stretch that to 6 months once their condition is stable. Because I perform in-office procedures, I see patients several times in the first few months before switching to a 6-month interval. By tracking how well current therapies are working at regular follow-up visits, we can adjust the management plan to ensure DED patients maintain a stable tear film and clear vision. References: Astolfi G, et al. J Clin Med. 2022;doi: 10.3390/jcm11061518 . Casey-Power S, et al. Pharmaceutics. 2022;doi: 10.3390/pharmaceutics14071479 . Fariselli C, et al. Clin Ophthalmol. 2018;doi: 10.2147/OPTH.S174290 . Liu Z, et al. Invest Ophthalmol Vis Sci. 2020;doi: 10.1167/iovs.61.10.26 . David Kading, OD, is CEO at Specialty Eye in Kirkland and Bellevue, Washington. Read more about
TearScience Frequently Asked Questions (FAQ)
When was TearScience founded?
TearScience was founded in 2005.
Where is TearScience's headquarters?
TearScience's headquarters is located at 5151 McCrimmon Parkway, Morrisville.
What is TearScience's latest funding round?
TearScience's latest funding round is Acquired.
How much did TearScience raise?
TearScience raised a total of $133.73M.
Who are the investors of TearScience?
Investors of TearScience include Johnson & Johnson, Investor Growth Capital, General Catalyst, EW Healthcare Partners, HealthCare Royalty Partners and 5 more.
Who are TearScience's competitors?
Competitors of TearScience include eSight, Cardiva Medical, PulmonX, Acelity, Powervision and 7 more.
Compare TearScience to Competitors
OcuSciences is developing a product to use images from the eye to detect diseases such as diabetes at an earlier stage.
Portaero, in stealth mode, is a medical devices firm, developing a device for the treatment of COPD (Chronic obstructive pulmonary disease).
Realistic Eye aims to provide a more natural appearance for the 750,000 patients in the US with an artificial eye that does not dilate and therefore appears unnatural. RealisticEye achieves these results by introducing a dilating artificial eye.
Valor Medical is a San Diego-based medical device company that has developed liquid embrolic technology for the treatment of cerebral aneurysms.
eSight is a company that focuses on low-vision assistive technology within the healthcare industry. The company's main product is a pair of smart glasses that enhance the vision of individuals with significant central vision loss, using a high-speed camera and advanced algorithms to optimize and enhance real-time footage. The company primarily serves the healthcare sector, particularly eye care professionals and individuals with various eye conditions. It was founded in 2006 and is based in Toronto, Ontario.
Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.